FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – Europe 03/2024”.
The Monitor is a month-to-month revealed overview of enterprise capital tendencies within the European Healthcare & Life Sciences sector.
As of the top of March 2025 we recognized the next present VC tendencies in Europe:
- Whole Healthcare & Life Sciences funding reached EUR 3,713m (+55% vs. 2024)
- Biotech/Pharma obtained 35% of the overall funding quantity (EUR 1,316m) with metabolic problems being the main indication (30%)
- In March, Isomorphic Labs (United Kingdom) secured the best transaction quantity with EUR 536m, adopted by Amboss (Germany) with EUR 240m and Augustine Therapeutics (Belgium) with EUR 78m
- The Sequence A financing spherical of EUR 536m for Isomorphic Labs (United Kingdom) is the biggest ever early-stage TechBio financing spherical in Europe
- GV (United States) is probably the most energetic investor (by deal quantity in 2025), adopted by Alphabet (United States) and Thrive Capital (United States)
To entry the complete report, please click on right here.
By Mathias Klozenbücher and Johannes Hyperlink